Global Age-relatedMacularDegeneration (ARMD) Drugs Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 124634
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Age-relatedMacularDegeneration (ARMD) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Age-relatedMacularDegeneration (ARMD) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Exudative ARMD accounting for % of the Age-relatedMacularDegeneration (ARMD) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Anti VEGF Drugs segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Age-relatedMacularDegeneration (ARMD) Drugs include Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, and Kanghong Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Age-relatedMacularDegeneration (ARMD) Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Anti VEGF Drugs

Photosensitive Drugs

Others

Market segment by Application, can be divided into

Exudative ARMD

Atrophy ARMD

Market segment by players, this report covers

Roche

Regeneron Pharmaceuticals

Bayer

Santen Oy

Kanghong Pharmaceuticals

Novartis

Eli Lilly and Company

TRACON Pharmaceuticals

Pfizer

GSK

BIOCAD

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Age-relatedMacularDegeneration (ARMD) Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Age-relatedMacularDegeneration (ARMD) Drugs, with revenue, gross margin and global market share of Age-relatedMacularDegeneration (ARMD) Drugs from 2019 to 2022.

Chapter 3, the Age-relatedMacularDegeneration (ARMD) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Age-relatedMacularDegeneration (ARMD) Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Age-relatedMacularDegeneration (ARMD) Drugs research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Age-relatedMacularDegeneration (ARMD) Drugs

1.2 Classification of Age-relatedMacularDegeneration (ARMD) Drugs by Type

1.2.1 Overview: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type in 2021

1.2.3 Anti VEGF Drugs

1.2.4 Photosensitive Drugs

1.2.5 Others

1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market by Application

1.3.1 Overview: Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Exudative ARMD

1.3.3 Atrophy ARMD

1.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size & Forecast

1.5 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast by Region

1.5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region, (2017-2022)

1.5.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Prospect (2017-2028)

1.5.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Prospect (2017-2028)

1.5.6 South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers

1.6.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints

1.6.3 Age-relatedMacularDegeneration (ARMD) Drugs Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.1.4 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Roche Recent Developments and Future Plans

2.2 Regeneron Pharmaceuticals

2.2.1 Regeneron Pharmaceuticals Details

2.2.2 Regeneron Pharmaceuticals Major Business

2.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.2.4 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Regeneron Pharmaceuticals Recent Developments and Future Plans

2.3 Bayer

2.3.1 Bayer Details

2.3.2 Bayer Major Business

2.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Bayer Recent Developments and Future Plans

2.4 Santen Oy

2.4.1 Santen Oy Details

2.4.2 Santen Oy Major Business

2.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.4.4 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Santen Oy Recent Developments and Future Plans

2.5 Kanghong Pharmaceuticals

2.5.1 Kanghong Pharmaceuticals Details

2.5.2 Kanghong Pharmaceuticals Major Business

2.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.5.4 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Kanghong Pharmaceuticals Recent Developments and Future Plans

2.6 Novartis

2.6.1 Novartis Details

2.6.2 Novartis Major Business

2.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.6.4 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Novartis Recent Developments and Future Plans

2.7 Eli Lilly and Company

2.7.1 Eli Lilly and Company Details

2.7.2 Eli Lilly and Company Major Business

2.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.7.4 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Eli Lilly and Company Recent Developments and Future Plans

2.8 TRACON Pharmaceuticals

2.8.1 TRACON Pharmaceuticals Details

2.8.2 TRACON Pharmaceuticals Major Business

2.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.8.4 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 TRACON Pharmaceuticals Recent Developments and Future Plans

2.9 Pfizer

2.9.1 Pfizer Details

2.9.2 Pfizer Major Business

2.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.9.4 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Pfizer Recent Developments and Future Plans

2.10 GSK

2.10.1 GSK Details

2.10.2 GSK Major Business

2.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.10.4 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 GSK Recent Developments and Future Plans

2.11 BIOCAD

2.11.1 BIOCAD Details

2.11.2 BIOCAD Major Business

2.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

2.11.4 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 BIOCAD Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Age-relatedMacularDegeneration (ARMD) Drugs Players Market Share in 2021

3.2.2 Top 10 Age-relatedMacularDegeneration (ARMD) Drugs Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Age-relatedMacularDegeneration (ARMD) Drugs Players Head Office, Products and Services Provided

3.4 Age-relatedMacularDegeneration (ARMD) Drugs Mergers & Acquisitions

3.5 Age-relatedMacularDegeneration (ARMD) Drugs New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Market Share by Type (2017-2022)

4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application (2017-2022)

5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2028)

6.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2028)

6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country

6.3.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2028)

6.3.2 United States Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

6.3.3 Canada Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

6.3.4 Mexico Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2028)

7.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2028)

7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country

7.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2028)

7.3.2 Germany Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

7.3.3 France Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

7.3.5 Russia Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

7.3.6 Italy Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2028)

8.2 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2028)

8.3 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Region

8.3.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Region (2017-2028)

8.3.2 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

8.3.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

8.3.4 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

8.3.5 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

8.3.7 Australia Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2028)

9.2 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2028)

9.3 South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country

9.3.1 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2028)

9.3.2 Brazil Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

9.3.3 Argentina Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2028)

10.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2028)

10.3 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Country

10.3.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2028)

10.3.2 Turkey Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

10.3.4 UAE Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) by Region (2017-2022)

Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Region (2023-2028)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 9. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Regeneron Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 11. Regeneron Pharmaceuticals Major Business

Table 12. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 13. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Bayer Corporate Information, Head Office, and Major Competitors

Table 15. Bayer Major Business

Table 16. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 17. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Santen Oy Corporate Information, Head Office, and Major Competitors

Table 19. Santen Oy Major Business

Table 20. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 21. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Kanghong Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 23. Kanghong Pharmaceuticals Major Business

Table 24. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 25. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Novartis Corporate Information, Head Office, and Major Competitors

Table 27. Novartis Major Business

Table 28. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 29. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors

Table 31. Eli Lilly and Company Major Business

Table 32. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 33. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. TRACON Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 35. TRACON Pharmaceuticals Major Business

Table 36. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 37. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Pfizer Corporate Information, Head Office, and Major Competitors

Table 39. Pfizer Major Business

Table 40. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 41. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. GSK Corporate Information, Head Office, and Major Competitors

Table 43. GSK Major Business

Table 44. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 45. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. BIOCAD Corporate Information, Head Office, and Major Competitors

Table 47. BIOCAD Major Business

Table 48. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions

Table 49. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 51. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 52. Breakdown of Age-relatedMacularDegeneration (ARMD) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 53. Age-relatedMacularDegeneration (ARMD) Drugs Players Head Office, Products and Services Provided

Table 54. Age-relatedMacularDegeneration (ARMD) Drugs Mergers & Acquisitions in the Past Five Years

Table 55. Age-relatedMacularDegeneration (ARMD) Drugs New Entrants and Expansion Plans

Table 56. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) by Type (2017-2022)

Table 57. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Type (2017-2022)

Table 58. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Forecast by Type (2023-2028)

Table 59. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2022)

Table 60. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Forecast by Application (2023-2028)

Table 61. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2022) & (USD Million)

Table 62. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2023-2028) & (USD Million)

Table 63. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2022) & (USD Million)

Table 64. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2023-2028) & (USD Million)

Table 65. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 66. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2023-2028) & (USD Million)

Table 67. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2022) & (USD Million)

Table 68. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2023-2028) & (USD Million)

Table 69. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2022) & (USD Million)

Table 70. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2023-2028) & (USD Million)

Table 71. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 72. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2023-2028) & (USD Million)

Table 73. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2022) & (USD Million)

Table 74. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2023-2028) & (USD Million)

Table 75. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2022) & (USD Million)

Table 76. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2023-2028) & (USD Million)

Table 77. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Region (2017-2022) & (USD Million)

Table 78. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Region (2023-2028) & (USD Million)

Table 79. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2022) & (USD Million)

Table 80. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2023-2028) & (USD Million)

Table 81. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2022) & (USD Million)

Table 82. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2023-2028) & (USD Million)

Table 83. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 84. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2023-2028) & (USD Million)

Table 85. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2017-2022) & (USD Million)

Table 86. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type (2023-2028) & (USD Million)

Table 87. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2017-2022) & (USD Million)

Table 88. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2023-2028) & (USD Million)

Table 89. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 90. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Picture

Figure 2. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type in 2021

Figure 3. Anti VEGF Drugs

Figure 4. Photosensitive Drugs

Figure 5. Others

Figure 6. Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application in 2021

Figure 7. Exudative ARMD Picture

Figure 8. Atrophy ARMD Picture

Figure 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Forecast (2017-2028) & (USD Million)

Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Region (2017-2028)

Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Region in 2021

Figure 13. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers

Figure 19. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints

Figure 20. Age-relatedMacularDegeneration (ARMD) Drugs Market Trends

Figure 21. Roche Recent Developments and Future Plans

Figure 22. Regeneron Pharmaceuticals Recent Developments and Future Plans

Figure 23. Bayer Recent Developments and Future Plans

Figure 24. Santen Oy Recent Developments and Future Plans

Figure 25. Kanghong Pharmaceuticals Recent Developments and Future Plans

Figure 26. Novartis Recent Developments and Future Plans

Figure 27. Eli Lilly and Company Recent Developments and Future Plans

Figure 28. TRACON Pharmaceuticals Recent Developments and Future Plans

Figure 29. Pfizer Recent Developments and Future Plans

Figure 30. GSK Recent Developments and Future Plans

Figure 31. BIOCAD Recent Developments and Future Plans

Figure 32. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Players in 2021

Figure 33. Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 34. Global Top 3 Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share in 2021

Figure 35. Global Top 10 Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share in 2021

Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 37. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Type in 2021

Figure 38. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Type (2023-2028)

Figure 39. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application in 2021

Figure 40. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Application (2023-2028)

Figure 41. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2017-2028)

Figure 42. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2017-2028)

Figure 43. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Country (2017-2028)

Figure 44. United States Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Canada Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2017-2028)

Figure 48. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2017-2028)

Figure 49. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Country (2017-2028)

Figure 50. Germany Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. France Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. United Kingdom Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Russia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Italy Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2017-2028)

Figure 56. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2017-2028)

Figure 57. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Region (2017-2028)

Figure 58. China Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Japan Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. India Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Australia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2017-2028)

Figure 65. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2017-2028)

Figure 66. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Country (2017-2028)

Figure 67. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Type (2017-2028)

Figure 70. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share by Application (2017-2028)

Figure 71. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Country (2017-2028)

Figure 72. Turkey Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. UAE Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Methodology

Figure 76. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

+1

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketquest.biz